Corvus Pharmaceuticals (CRVS) Research & Development (2015 - 2026)

Corvus Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 32.34% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $28.8 million, a 65.14% increase from a year earlier, with the FY2023 full-year figure at $16.5 million, down 32.46% from the prior year.
• Research & Development retreated to $5.0 million in Q1 2026 per CRVS's latest filing, from $8.5 million in the prior quarter.
• Across five years, Research & Development topped out at $10.4 million in Q3 2022 and bottomed at $665000.0 in Q1 2024.
• The 5-year median for Research & Development is $4.9 million (2022), against an average of $5.3 million.
• Across the five-year window, Research & Development plunged 85.52% in 2024 and jumped 1020.75% in 2025, its largest moves.
• Year by year, Research & Development stood at $4.1 million in 2022, then retreated by 1.99% to $4.0 million in 2023, then surged by 30.58% to $5.2 million in 2024, then jumped by 61.89% to $8.5 million in 2025, then sank by 40.35% to $5.0 million in 2026.
• Per Business Quant, the three latest CRVS Research & Development figures stand at $5.0 million (Q1 2026), $8.5 million (Q3 2025), and $7.9 million (Q2 2025).